| Mortality and survival | 18 | 8 | 15 | 6 | 3 | 2 | NA | NA |
| Survival | 2 | | 2 | | 0 | | NA | |
| Overall survival | 5 | | 3 | | 2 | | NA | |
| Cause- (or disease) specific survival | 6 | | 5 | | 1 | | NA | |
| Relative survival | 1 | | 1 | | 0 | | NA | |
| Metastasis-free survival | 2 | | 2 | | 0 | | NA | |
| Progression-free survival | 1 | | 1 | | 0 | | NA | |
| Biochemical recurrence-free survival | 1 | | 1 | | 0 | | NA | |
| Outcomes relating to neoplasms | 19 | 7 | 18 | 6 | 1 | 1 | 0 | 0 |
| (Change in) prostate-specific antigen (PSA) levels | 3 | | 3 | | 0 | | 0 | |
| Measurable disease response | 1 | | 1 | | 0 | | 0 | |
| Time to progression | 2 | | 2 | | 0 | | 0 | |
| Disease progression/Progression rate | 2 | | 2 | | 0 | | 0 | |
| Progression-free probability | 1 | | 1 | | 0 | | 0 | |
| Development of metastases | 1 | | 1 | | 0 | | 0 | |
| Metastases-free probability | 1 | | 1 | | 0 | | 0 | |
| Symptomatic skeletal event | 1 | | 0 | | 1 | | 0 | |
| Local disease | 1 | | 1 | | 0 | | 0 | |
| Positive surgical margins | 1 | | 1 | | 0 | | 0 | |
| Response duration | 1 | | 1 | | 0 | | 0 | |
| Failure-free probability | 1 | | 1 | | 0 | | 0 | |
| Development of castration-resistant disease | 1 | | 1 | | 0 | | 0 | |
| Treatment failure | 2 | | 2 | | 0 | | 0 | |
| Renal and urinary outcomes | 13 | 6 | 8 | 3 | 3 | 2 | 2 | 1 |
| Urinary incontinence | 4 | | 2 | | 1 | | 1 | |
| Urinary obstruction/irritation | 3 | | 1 | | 1 | | 1 | |
| Urinary symptoms | 1 | | 0 | | 1 | | 0 | |
| Voiding behaviour | 1 | | 1 | | 0 | | 0 | |
| Haematuria | 1 | | 1 | | 0 | | 0 | |
| Pelvic pain | 1 | | 1 | | 0 | | 0 | |
| Lymphedema | 1 | | 1 | | 0 | | 0 | |
| Urinary functioning | 1 | | 1 | | 0 | | 0 | |
| Gastrointestinal outcomes | 6 | 5 | 3 | 2 | 2 | 2 | 1 | 1 |
| Bowel symptoms | 3 | | 0 | | 2 | | 1 | |
| Faecal incontinence | 1 | | 1 | | 0 | | 0 | |
| Bowel functioning | 1 | | 1 | | 0 | | 0 | |
| Diarrhoea | 1 | | 1 | | 0 | | 0 | |
| Endocrine outcomes | 3 | 3 | 0 | 0 | 2 | 2 | 1 | 1 |
| Hormonal symptoms | 3 | | 0 | | 2 | | 1 | |
| Reproductive system outcomes | 6 | 6 | 3 | 3 | 2 | 2 | 1 | 1 |
| Erectile/sexual function | 2 | | 2 | | 0 | | 0 | |
| Erectile/sexual dysfunction (impotence) | 3 | | 1 | | 1 | | 1 | |
| Sexual symptoms | 1 | | 0 | | 1 | | 0 | |
| General outcomes | 8 | 3 | 3 | 1 | 3 | 1 | 2 | 1 |
| Pain | 2 | | 0 | | 1 | | 1 | |
| Fatigue | 2 | | 0 | | 1 | | 1 | |
| Bone pain | 1 | | 1 | | 0 | | 0 | |
| Weight loss | 1 | | 1 | | 0 | | 0 | |
| Anaemia | 1 | | 1 | | 0 | | 0 | |
| Performance status | 1 | | 0 | | 1 | | 0 | |
| Physical functioning | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Physical wellbeing/functioning | 3 | | 1 | | 1 | | 1 | |
| Emotional functioning/wellbeing | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 |
| Mental/emotional wellbeing/functioning | 4 | | 2 | | 1 | | 1 | |
| Social functioning | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Social functioning | 1 | | 1 | | 0 | | 0 | |
| Role functioning | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Role functioning | 1 | | 1 | | 0 | | 0 | |
| Global quality of life | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 |
| Quality of life | 6 | | 6 | | 0 | | 0 | |
| Economic outcomes | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Cost-effectiveness | 1 | | 1 | | 0 | | 0 | |
| Costs | 1 | | 1 | | 0 | | 0 | |
| Need for intervention | 4 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Need for salvage therapy | 1 | | 1 | | 0 | | 0 | |
| Need for curative treatment | 1 | | 1 | | 0 | | 0 | |
| Need for pain medication | 1 | | 0 | | 1 | | 0 | |
| Procedures need for local progression | 1 | | 0 | | 1 | | 0 | |
| Delivery of care | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Time to treatment failure | 1 | | 1 | | 0 | | 0 | |
| Adverse events/effects | 8 | 6 | 6 | 4 | 2 | 2 | 0 | 0 |
| Adverse events | 3 | | 2 | | 1 | | 0 | |
| Perioperative deaths | 1 | | 1 | | 0 | | 0 | |
| Thromboembolic disease | 1 | | 1 | | 0 | | 0 | |
| Bothersome or symptomatic urethral or anastomotic stricture | 1 | | 1 | | 0 | | 0 | |
| Side-effects of hormonal therapy | 1 | | 1 | | 0 | | 0 | |
| Major systemic therapy effects | 1 | | 0 | | 1 | | 0 | |
| Total | 103 | | 72 | | 22 | | 9 | |
